pharma · Nicotine use
SWEDISH ORPHAN BIOVITRUM
Swedish Orphan Biovitrum Pty Ltd
Swedish Orphan Biovitrum is a pharma organization headquartered in AU. Primary therapeutic focus areas include Nicotine use. NovaPharmaNews links 2 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this e
Company details
- Status
- Public
- HQ
- IT
- Employees
- 3
- Programs
- 2
- Drugs
- 10
- Patents
- 0
NI-501; emapalumab, NI-501; emapalumab
Phase 3 · small molecule · Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).
NI-501; emapalumab, NI-501; emapalumab for Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE). is a Phase 3 program (small_molecule) at Swedish Orphan Biovitrum Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code NI-0501-14
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Swedish Orphan Biovitrum Pty Ltd
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Macrophage activation syndrome (MAS) in the context of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult onset Still's disease (AOSD). MAS in the context of pediatric and adult Systemic Lupus Erythematosus (SLE).
- Status
- active
- Trials
- 1